company background image
LYTI

Lytix Biopharma OB:LYTIX Stock Report

Last Price

kr9.50

Market Cap

kr380.6m

7D

-5.0%

1Y

n/a

Updated

18 May, 2022

Data

Company Financials
LYTIX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LYTIX Stock Overview

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.

Lytix Biopharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Lytix Biopharma
Historical stock prices
Current Share Pricekr9.50
52 Week Highkr21.50
52 Week Lowkr9.00
Beta0
1 Month Change-9.52%
3 Month Change-19.49%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-48.93%

Recent News & Updates

Jan 25
We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Sep 14
We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

LYTIXNO BiotechsNO Market
7D-5.0%0.7%3.5%
1Yn/a-47.0%16.1%

Return vs Industry: Insufficient data to determine how LYTIX performed against the Norwegian Biotechs industry.

Return vs Market: Insufficient data to determine how LYTIX performed against the Norwegian Market.

Price Volatility

Is LYTIX's price volatile compared to industry and market?
LYTIX volatility
LYTIX Average Weekly Movement9.0%
Biotechs Industry Average Movement8.6%
Market Average Movement7.5%
10% most volatile stocks in NO Market12.6%
10% least volatile stocks in NO Market4.3%

Stable Share Price: LYTIX is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LYTIX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20038Oystein Rekdalhttps://www.lytixbiopharma.com

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.

Lytix Biopharma Fundamentals Summary

How do Lytix Biopharma's earnings and revenue compare to its market cap?
LYTIX fundamental statistics
Market Capkr380.65m
Earnings (TTM)-kr48.05m
Revenue (TTM)kr6.35m

60.0x

P/S Ratio

-7.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LYTIX income statement (TTM)
Revenuekr6.35m
Cost of Revenuekr0
Gross Profitkr6.35m
Other Expenseskr54.40m
Earnings-kr48.05m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-1.20
Gross Margin100.00%
Net Profit Margin-756.80%
Debt/Equity Ratio0.0%

How did LYTIX perform over the long term?

See historical performance and comparison

Valuation

Is Lytix Biopharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.01x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: LYTIX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: LYTIX is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LYTIX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LYTIX is good value based on its PB Ratio (2x) compared to the NO Biotechs industry average (4x).


Future Growth

How is Lytix Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


76.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lytix Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Lytix Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LYTIX is currently unprofitable.

Growing Profit Margin: LYTIX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LYTIX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.

Accelerating Growth: Unable to compare LYTIX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LYTIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: LYTIX has a negative Return on Equity (-25.34%), as it is currently unprofitable.


Financial Health

How is Lytix Biopharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LYTIX's short term assets (NOK203.0M) exceed its short term liabilities (NOK13.3M).

Long Term Liabilities: LYTIX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LYTIX is debt free.

Reducing Debt: LYTIX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LYTIX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: LYTIX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.2% each year


Dividend

What is Lytix Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LYTIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LYTIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LYTIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LYTIX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LYTIX has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Oystein Rekdal

19.33yrs

Tenure

kr7,331,000

Compensation

Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...


CEO Compensation Analysis

Compensation vs Market: Oystein's total compensation ($USD747.80K) is above average for companies of similar size in the Norwegian market ($USD331.54K).

Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LYTIX's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: LYTIX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: LYTIX only recently listed within the past 12 months.


Top Shareholders

Company Information

Lytix Biopharma AS's employee growth, exchange listings and data sources


Key Information

  • Name: Lytix Biopharma AS
  • Ticker: LYTIX
  • Exchange: OB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr380.649m
  • Shares outstanding: 40.07m
  • Website: https://www.lytixbiopharma.com

Number of Employees


Location

  • Lytix Biopharma AS
  • Sandakerveien 138
  • Oslo
  • Oslo
  • 484
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.